Press releases

28 Mar 2022

U.S. FDA Approves FINTEPLA[®] ▼(fenfluramine) Oral Solution for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

26 Mar 2022

New Long-Term Complete Skin Clearance Data for BIMZELX[®]▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

25 Mar 2022

Disposal of own shares

25 Mar 2022

New UCB data analysis adds to demonstrated efficacy of romosozumab▼ to reduce the risk of fractures

25 Mar 2022

WCO-IOF-ESCEO 2022 – Post-hoc analysis on the proportion of patients treated with EVENITY[® ]▼(romosozumab) reaching surrogate threshold effect that predicts fracture risk reduction

18 Mar 2022

Transparency notification FMR LLC

Press releases

Press releases

Search Press releases

U.S. FDA Approves FINTEPLA[®] ▼(fenfluramine) Oral Solution for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

New Long-Term Complete Skin Clearance Data for BIMZELX[®]▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Disposal of own shares

New UCB data analysis adds to demonstrated efficacy of romosozumab▼ to reduce the risk of fractures

WCO-IOF-ESCEO 2022 – Post-hoc analysis on the proportion of patients treated with EVENITY[® ]▼(romosozumab) reaching surrogate threshold effect that predicts fracture risk reduction

Transparency notification FMR LLC

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

U.S. FDA Approves FINTEPLA[®] ▼(fenfluramine) Oral Solution for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

New Long-Term Complete Skin Clearance Data for BIMZELX[®]▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Disposal of own shares

New UCB data analysis adds to demonstrated efficacy of romosozumab▼ to reduce the risk of fractures

WCO-IOF-ESCEO 2022 – Post-hoc analysis on the proportion of patients treated with EVENITY[® ]▼(romosozumab) reaching surrogate threshold effect that predicts fracture risk reduction

Transparency notification FMR LLC

Choose a Country